The Quad Investors Network Launches with Advisory Board, Expert Groups
20.5.2023 17:43:00 EEST | Business Wire | Press release
The Quad Investors Network formally launched today in parallel with the Quad Leaders meeting in Hiroshima, Japan. The Network is an independent forum of public, private, and philanthropic stakeholders from the four Quad nations, created to foster cooperation, collaboration, and co-investment into critical technologies and supply chain resilience to develop innovative solutions to the greatest economic and security challenges in the Indo-Pacific region. Membership in the network is by invitation only.
Governments participating in the security dialogue, a strategic endeavor between Australia, India, Japan, and the United States, also jointly welcomed the formation of the board and the network’s continued efforts to expand capital and partnership opportunities in critical and emerging technologies across the Quad.
“Critical and emerging technologies will profoundly shape our future. By seeking to accelerate the development and manufacturing of these technologies, from semiconductors to quantum to clean energy, the Quad Investors Network demonstrates the tremendous potential of the Quad nations to mobilize world-class talent and investment to foster a more prosperous, resilient, and innovative Indo-Pacific,” said Jake Sullivan, U.S. National Security Advisor.
As part of the launch, the Quad Investors Network announced the formation of an Advisory Board, composed of world-class business, investment, and thought leaders from the four Quad nations. The Advisory Board includes former Telstra CEO Andy Penn AO; former Australian Ambassador to the United States Arthur Sinodinos AO; Founder and CEO of Breyer Capital Jim Breyer; former Bell Labs President Jeong Kim; Chairman Emeritus of JSR Corporation Koshiba Mitsunobu; and Japan Business Federation Managing Director Hara Ichiro.
“The Quad Investors Network serves as an important, exciting forum for executives, investors, and technologists to collaborate and generate greater co-investment in critical and emerging technologies. These technologies will only grow in importance in the future, and I am honored to be a member of the network’s Advisory Board,” said former Telstra CEO Andy Penn.
The Quad Investors Network also established five expert working groups focused on artificial intelligence, semiconductors, clean energy and critical minerals, mobile networks, and quantum information sciences.
Entrepreneur and investor Karl Mehta will serve as the inaugural Chairman of the Quad Investors Network. Mehta is a serial entrepreneur, author, investor, engineer, and civil servant with more than 30 years of experience in founding, building, and funding technology companies in the U.S. and international markets.
“I am honored to lead, and be a part, of such an august group of individuals and organizations which have come together to work on some of the most pressing critical technology issues facing the Quad,” said Mehta. “I look forward to making further progress and contributing to the economic and national security of the four Quad nations through our efforts.”
Full List of the Quad Investors Network Advisory Board:
- Thomas Bell, CEO of Leidos
- Jim Breyer, Founder and CEO of Breyer Capital
- Kris Gopalakrishnan, Chairman of Axilor Ventures
- Hara Ichiro, Managing Director of Japan Business Federation
- Hon. Joe Hockey, Founding Partner and President of Bondi Partners
- Ashok Jacob, Executive Chairman and Portfolio Manager for Ellerston Capital
- Lydia Jett, Managing Partner at Softbank Investment Advisers
- Jeong Kim, Chairman of Kiswe Mobile Inc.
- Koshiba Mitsunobu, Chairman Emeritus of JSR Corporation
- Arun Kumar, Managing Partner of Celesta Capital
- Paul Kwan, General Partner at General Catalyst
- Nakahama Fumitaka, Managing Corporate Executive and Group Head of Global Corporate and Investment Banking Business at MUFG
- Jeff Nuechterlein, Managing Partner of Nue Capital LLC
- Andy Penn AO, Former CEO of Telstra
- Bec Shrimpton, Defence Strategy and National Security Director at the Australian Strategic Policy Institute
- Hon. Arthur Sinodinos AO, Former Australian Ambassador to the United States
- Hon. Sugiyama Shinsuke, Former Japanese Ambassador to the United States
- Yanase Tadao, Senior Executive Vice President at Nippon Telegraph and Telephone Corporation
- Ankur Verma, Senior Vice President at Tata Sons
About The Quad Investors Network: The Quad Investors Network (“The Network”) was formed to develop innovative solutions to the greatest economic and security challenges facing the Quad nations in the Indo-Pacific region through joint research, co-investments, and strategic partnerships. The network will be an independent, membership forum composed of leading industry, government, capital market, and academic organizations from the Quad nations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230520005025/en/
Contact information
Alex El-Fakir
201-328-2930
info@quadinvestorsnetwork.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
